Letters to the Editor

DEFICIENCY OF ESSENTIAL FATTY ACIDS AND ATHEROSCLEROSIS, ETCETERA

This review is about the role of arachidonic acid (ArA) in foetal and early growth and development. In 1975 and ‘76, we reported the preferential incorporation of ArA into the developing brain of rat pups, its conservation as a principal component in the brains of 32 mammalian species and the high proportion delivered by the human placenta for foetal nutrition, compared to its parent linoleic acid (LA). ArA is quantitatively the principal acyl component of membrane lipids from foetal red cells, mononuclear cells, astrocytes, endothelium, and placenta. Functionally, we present evidence that ArA, but not DHA, relaxes the foetal mesenteric arteries. The placenta biomagnifies ArA, doubling the proportion of the maternal level in cord blood. The proportions of ArA and its allies (di-homo-gamma-linolenic acid (DGLA), adrenic acid and ω6 docosapentaenoic acid) are similar or higher than the total of ω3 fatty acids in human milk, maintaining the abundant supply to the developing infant. Despite the evidence of the importance of ArA, the European Food Standard Agency, in 2014 rejected the joint FAO and WHO recommendation on the inclusion of ArA in infant formula, although they recommended DHA. The almost universal dominance of ArA in the membrane phosphoglycerides during human organogenesis and prenatal growth suggests that the importance of ArA and its allies in reproductive biology needs to be re-evaluated urgently.

Cardiovascular diseases are a leading cause of death worldwide. Polyunsaturated fatty acids (PUFA), particularly n−3 PUFA, are widely regarded as cardioprotective. We review and compare evidence on the benefits, and in some cases adverse effects, of n−3 and n−6 PUFA in cardiovascular disease prevention, and provide insight into potential molecular mechanisms of these benefits. Hypolipidemic, anti-inflammatory, anti-arrhythmic and anti-aggregatory properties of these fatty acids confer cardiovascular protection. Unresolved inflammation plays an important role in the progression of cardiovascular diseases. Specialized pro-resolving mediators, including resolvins, maresins, protectins, and lipoxins, produced by the oxygenation of n−3 and n−6 PUFA, play an important role in cardiovascular benefits mediated by PUFA. We also review current data on molecular mechanisms underlying the protective effects of these lipid mediators. Understanding molecular pathways of both n−3 and n−6 PUFA is important for advancing preventive and therapeutic strategies for cardiovascular diseases.

Based on our developed sodium hyaluronate-functionalized urea-formaldehyde (HA-UF) monolith, a silver nanoparticles-coated monolithic column has been fabricated via the interaction between silver nanoparticles (Ag NPs) and HA. The successful coating of Ag NPs on the parent monolith was proven by SEM, EDAX, UV–vis spectrum and XPS. Nitrogen adsorption desorption isotherms and Barret-Joyner-Halenda (BJH) pore size distributions of the parent and resultant monolith were also performed. Due to the Ag⁺-like affinity interaction caused by the contact of unsaturated compounds and Ag NPs, the Ag NPs-coated monolith showed satisfactory extraction efficiency towards these compounds, and was applied for in-tube solid-phase microextraction (SPME) of monounsaturated fatty acid methyl esters (MUFAMEs). Several factors for in-tube SPME, such as ACN percentage in the sampling solution, elution volume, sampling and elution flow rate, were investigated with respect to the extraction efficiency of model MUFAMEs. Under the optimized SPME conditions, a simple in tube SPME-Ag⁺-HPLC method for detection of model MUFAMEs has been proposed, the limits of detection (LODs) were less than 5.2 μg/kg, and the recoveries of spiked French fry samples were ranged from 86.6% to 96.1% with relative standard deviations (RSDs) less than 5.2%. This study provided an Ag NPs-coated monolith with good reproducibility and repeatable extraction performance, and developed an efficient method for in-tube SPME of MUFAMEs in practical food samples.

Despite more than a century of research, cardiovascular disease (CVD) and coronary heart disease (CHD) are the leading causes of death in the developing world. Since the early days of CVD research, the underlying cause and putative prevention strategies remain elusive. This chapter discusses the history of the lipid hypothesis, from the initial observations of Anitschkow and Chalatow to the industrious work of Gofman and the further studies of Ancel Keys, who endeavored to discover the role of cholesterol and saturated fat in CVD. The Seven Countries Study identified diet, saturated fat, and cholesterol as the underlying causes of CVD development. This chapter delivers an overview of the early research that formed the “lipid hypothesis,” which led to the development of modern treatment and prevention strategies for CVD.

In this report, an overview of the health benefits of omega-3 long-chain (≥C₂₀) polyunsaturated fatty acids (n-3 LC-PUFA) and recent progress in using alpha linolenic acid (ALA) rich sources derived from oilseeds to enhance productive performance, n-3 PUFA profiles and sensory properties of lamb for human consumption is reviewed. Omega-3 LC-PUFA can prevent mental health issues and chronic human disorders including cancer, cardiovascular and inflammatory diseases. The median amount of n-3 LC-PUFA consumption is generally lacking in Western diets. More attention is now being paid to the use of innovative nutritional strategies to improve PUFA content in ruminants, which could subsequently increase the content of health-benefitting n-3 LC-PUFA for human consumption. The richest sources of dietary n-3 LC-PUFA are derived from marine products, while forage and oilseeds such as flaxseed, canola, and their oils are abundant in ALA. Numerous studies have shown that dietary ALA increases n-3 LC-PUFA levels of edible tissues. However, other studies concluded that ALA rich supplementation led to no differences in tissue FA profiles because of extensive biohydrogenation of dietary ALA, limited conversion from ALA to n-3 LC-PUFA and low incorporation of n-3 LC-PUFA into edible tissues. Generally, the inclusion of ALA rich sources in lamb diets potentially increases ALA content in lamb. It is proposed that supplementing ruminants with ALA-rich sources at or below 6% can promote n-3 PUFA profiles in lamb and is unlikely to have negative effects on feed intake, growth, carcass and sensory properties.

Therapeutic implications of marine omega-3 highly unsaturated fatty acids (HUFA) in cardiovascular disease are still discussed controversially. Several clinical trials report divergent findings and thus leave ambiguity on the meaning of oral omega-3 therapy. Potential prognostic indications of HUFA treatment have been predominantly studied in coronary artery disease, sudden cardiac death, ventricular arrhythmias, atrial fibrillation and heart failure of various origin. It is suspected that increased ventricular wall stress is crucially involved in the prognosis of heart failure. Increased wall stress and an unfavorable myocardial remodeling is associated with an increased risk of arrhythmias by stretch-activated membrane ion channels. Integration of HUFA into the microenvironment of cardiomyocyte ion channels lead to allosteric changes and increase the electrical stability. Increased ventricular wall stress appears to be involved in the local myocardial as well as in the hepatic fatty acid metabolism, i.e. a cardio-hepatic syndrome. Influences of an altered endogenous HUFA metabolism and an inverse shift of the fatty acid profile was underrated in the past. A better understanding of these interacting endogenous mechanisms appears to be required for interpreting the findings of recent experimental and clinical studies. The present article critically reviews major studies on basic pathophysiological mechanisms and treatment effects in clinical trials.